PMID: 9337946Aug 1, 1997Paper

Cost-effectiveness of clozapine. A UK clinic-based study

The British Journal of Psychiatry : the Journal of Mental Science
K J Aitchison, Robert Kerwin

Abstract

Schizophrenia is highly expensive in calculable and incalculable costs. Measures which impact the cost in the most severely affected are likely to produce the greatest cost reductions. Studies regarding clozapine in the USA have demonstrated clear cost-effectiveness, despite the high prescription costs. There are no prior UK studies. We performed a cost-effectiveness analysis comparing the three years prior to commencing clozapine to the period following establishment of clozapine treatment (mean 36.4 months) for 26 patients with chronic schizophrenia or schizoaffective disorder. There was a significant improvement in all clinical ratings applied (and a mean net saving of ponds 3768 per annum). The cost-effectiveness of clozapine was double that of conventional neuroleptics (15.2 pre-, 33.0 post-clozapine, P < 0.005). As a naturalistic study our data provide valuable information on the cost-effectiveness of clozapine in the UK. Our methodology could be applied in a community setting or in the study of another atypical neuroleptic.

References

Jan 1, 1989·Schizophrenia Bulletin·P Allebeck
Jun 1, 1974·Journal of Abnormal Child Psychology·R M Dreger
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Aug 1, 1994·Addiction·G Godfrey
Dec 1, 1994·The American Journal of Psychiatry·J A LiebermanJ M Kane
Nov 1, 1993·The American Journal of Psychiatry·H Y MeltzerB Snitz

❮ Previous
Next ❯

Citations

Apr 23, 2002·The Journal of Mental Health Policy and Economics·Simon M. Gilbody, Mark Petticrew
May 4, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Simon SurguladzeMichael J Travis
Jun 17, 1998·Biological Psychiatry·J LaurielloA Pfefferbaum
Feb 19, 1999·Epidemiologia e psichiatria sociale·M Percudani, M Knapp
Jun 10, 2000·Quality in Health Care : QHC·C AdamsR Lewis
Nov 4, 2004·CNS Drugs·Aileen O'Brien
Apr 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Karen P HayhurstShon W Lewis
Jun 5, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Andy DugganRobert Kerwin
Feb 18, 2016·CNS Drugs·Jimmi NielsenDavid Taylor
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·D Lecompte, R F Cookson
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·D Taylor, K Aitchison
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
May 4, 2004·Current Medical Research and Opinion·Stephen Layton, Martin Barbeau
Apr 22, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Marco BarbieriAdrian Towse
Jul 22, 1998·The Australian and New Zealand Journal of Psychiatry·M Tobin, I Hickie
Feb 24, 2010·Journal of Psychopharmacology·Katherine J AitchisonPaul McCrone
Jul 4, 2002·Journal of Psychopharmacology·K P HayhurstS W Lewis
Oct 31, 2002·The Australian and New Zealand Journal of Psychiatry·Leslie R H DrewDonna M Hodgson
Oct 31, 2002·Human Psychopharmacology·Matteo BalestrieriCesario Bellantuono
Jun 15, 2017·The Cochrane Database of Systematic Reviews·Selvizhi SubramanianNick Huband
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·P McCroneS Johnson
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·M Knapp
Aug 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·G Robert, P Kennedy
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R W Kerwin, K J Aitchison
Feb 17, 1998·The British Journal of Psychiatry : the Journal of Mental Science·D M Taylor
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Adib EssaliJohn Rathbone
Aug 22, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·J LynchJ S Hellewell
Jan 5, 2002·The Journal of Nervous and Mental Disease·M J SernyakG Ripper
Sep 23, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mattia VeroneseOliver Howes
Nov 2, 1999·The Australian and New Zealand Journal of Psychiatry·L R DrewK M Griffiths
Nov 22, 2019·Irish Journal of Psychological Medicine·P KirwanC McDonald
Mar 12, 1999·British Journal of Clinical Pharmacology·M CampbellS H Thomas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The British Journal of Psychiatry : the Journal of Mental Science
L M Davies, M F Drummond
Schizophrenia Bulletin
S M Evers, A J Ament
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
M Seshamani
© 2021 Meta ULC. All rights reserved